Skip To Main Content
Koualy Sanogo on Muck Rack

Koualy Sanogo

As seen in: PLOS, The Lancet, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Koualy

Contact Koualy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Life cycle assessment of a clinical malaria trial in Mali reveals large environmental impacts of electricity consumption and international travel

|
By Almahamoudou Mahamar, Emma J. Kooistra, Kjerstin Lanke, Koualy Sanogo
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Citation: Smit MJ, Mahamar A, Kooistra E, Lanke K, Sanogo K, Okedy PW, et al. (2025) Life cycle assessment of a clinical malaria trial in Mali reveals large environmental impacts of electricity consumption and international travel. PLOS Sustain Transform 4(2): e0000131.
Open in Who Shared Issue with article?

The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data.

|
By Jordache Ramjith, Almahamoudou Mahamar, Kjerstin Lanke, Koualy Sanogo
| medRxiv
The authors have declared no competing interest. The original studies were registered with ClinicalTrials.gov (NCT01743820, NCT02831023, NCT04049916, NCT04609098, NCT05081089 and NCT05550909). Yes I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared Issue with article?

Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial - The Lancet Microbe

|
By Will Stone Verified, Almahamoudou Mahamar, Koualy Sanogo, Youssouf Sinaba
| The Lancet Verified
Summary Background Tafenoquine was recently approved as a prophylaxis and radical cure for Plasmodium vivax infection, but its Plasmodium falciparum transmission-blocking efficacy is unclear. We aimed to establish the efficacy and safety of three single low doses of tafenoquine in combination with dihydroartemisinin–piperaquine for reducing gametocyte density and transmission to mosquitoes.
Open in Who Shared Issue with article?
See all 4 articles